GI Innovation 358570.KQ · KRW

Its shares trade on KOSDAQ under the ticker 358570.KQ. It has been listed since 30 March 2023. In the fiscal year to 31 December 2025, it reported revenue of ₩5.84bn and a net loss of ₩35.13bn. At that date it held total assets of ₩127.46bn and shareholders' equity of ₩116.49bn.

GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Myeong Ho JangCo-President, Co-Chief Executive Officer, Director, since 2025
• Ms. Su Yeon NamCo-President, Director
• Mr. Jun Ho HongCo-Chief Executive Officer, Director
• Mr. Jin Man KimChief Financial Officer, Assistant Managing Director
• Mr. Yeong Gyu ChoVice President
• Mr. Yeong Jun GohManaging Director
• Mr. Guk Hwan KimAssistant Managing Director
• Mr. Gyeong Hwa LeeAssistant Managing Director
• Mr. Yeong Min OhAssistant Managing Director
• Ms. Na Ri YoonAssistant Managing Director
• Mr. Geun Yong AhnNon-Executive Independent Director
• Mr. Byeong Cheol KimNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.